Target
Hormone Receptors (HR)
3 abstracts
Abstract
Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.Org: American University of Beirut Medical Center, National Cancer Centre of Singapore, Acıbadem Research Institute of Senology, Medical Oncology, Seoul National University Hospital, Independent Patient Advocate,
Abstract
Survival in patients with brain metastasis secondary to breast cancer from Saudi Arabia.Org: Faculty of Medicine, Cairo University, King Abdulaziz University, Jeddah, Saudi Arabia,
Abstract
Associations among anesthesia-induced brain biomarkers during surgery, preoperative exposure to cancer therapeutics, and clinical outcomes.Org: Massachusetts General Hospital, Beth Israel Deaconess Medical Center, The University of Oklahoma Stephenson Cancer Center,